TY - JOUR
T1 - Effect of human amniotic fluid stem cells on kidney function in a model of chronic kidney disease
AU - George, Sunil K.
AU - Abolbashari, Mehran
AU - Kim, Tae Hyoung
AU - Zhang, Chao
AU - Allickson, Julie
AU - Jackson, John D.
AU - Lee, Sang Jin
AU - Ko, In Kap
AU - Atala, Anthony
AU - Yoo, James J.
N1 - Funding Information:
This study was supported, in part, by the State of North Carolina and the Wake Forest Institute for Regenerative Medicine. We thank Jennifer Huling, Cathy Mathis, Adam Wilson, Tiffaney Bledsoe, Cara Clouse, Cynthia V. Horne and Tsghe Abraha for technical assistance. We also thank Karen Klein, MA, in the Wake Forest Clinical and Translational Science Institute (UL1 TR001420; PI: McClain) for editorial assistance.
Publisher Copyright:
© Copyright 2019, Mary Ann Liebert, Inc., publishers.
PY - 2019/11
Y1 - 2019/11
N2 - Kidney disease is a major medical problem globally. Chronic kidney disease (CKD) is a progressive loss of kidney function. It causes accumulation of waste and fluid in the body, eventually resulting in kidney failure as well as damaging other organs. Although dialysis and kidney transplantation have been used as primary treatments for renal disease, dialysis does not restore full renal function, and there is a shortage of donor kidneys for transplantation. Recent advances in cell-based therapies have offered a means to augment and restore renal function. Various types of cells have been tested to evaluate their therapeutic effects on injured kidneys. Among various types of cells, amniotic fluid stem cells (AFSCs) share advantages of both embryonic and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects, which may allow their future therapeutic use as an "off-the-shelf" cell source. AFSC presents advantages of both conventional pluripotent and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects. This study demonstrates that administration of human-derived AFSC facilitates functional and structural improvement in a rat model of CKD, and suggests that cell therapy with AFSC has potential as a therapeutic strategy to recover renal function in patients with CKD. Patients with chronic kidney disease (CKD) have limited treatment options, and renal transplantation is the only definitive treatment method that restores kidney function. However, challenges associated with transplantation, including donor organ shortage, rejection, and life-long immunosuppression, remain a problem. Recently, stem cell-based therapies have been proposed as an alternative approach to augment and restore renal function. In this study, we used human-derived amniotic fluid stem cells (AFSCs) to treat CKD in a rat model and demonstrated that AFSC treatment facilitated positive effects in terms of improvements of renal function.
AB - Kidney disease is a major medical problem globally. Chronic kidney disease (CKD) is a progressive loss of kidney function. It causes accumulation of waste and fluid in the body, eventually resulting in kidney failure as well as damaging other organs. Although dialysis and kidney transplantation have been used as primary treatments for renal disease, dialysis does not restore full renal function, and there is a shortage of donor kidneys for transplantation. Recent advances in cell-based therapies have offered a means to augment and restore renal function. Various types of cells have been tested to evaluate their therapeutic effects on injured kidneys. Among various types of cells, amniotic fluid stem cells (AFSCs) share advantages of both embryonic and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects, which may allow their future therapeutic use as an "off-the-shelf" cell source. AFSC presents advantages of both conventional pluripotent and adult stem cells, such as pluripotent activity, remarkable plasticity, and immunomodulatory effects. This study demonstrates that administration of human-derived AFSC facilitates functional and structural improvement in a rat model of CKD, and suggests that cell therapy with AFSC has potential as a therapeutic strategy to recover renal function in patients with CKD. Patients with chronic kidney disease (CKD) have limited treatment options, and renal transplantation is the only definitive treatment method that restores kidney function. However, challenges associated with transplantation, including donor organ shortage, rejection, and life-long immunosuppression, remain a problem. Recently, stem cell-based therapies have been proposed as an alternative approach to augment and restore renal function. In this study, we used human-derived amniotic fluid stem cells (AFSCs) to treat CKD in a rat model and demonstrated that AFSC treatment facilitated positive effects in terms of improvements of renal function.
KW - amniotic fluid
KW - chronic kidney disease
KW - kidney regeneration
KW - stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85074554206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074554206&partnerID=8YFLogxK
U2 - 10.1089/ten.tea.2018.0371
DO - 10.1089/ten.tea.2018.0371
M3 - Article
C2 - 30829146
AN - SCOPUS:85074554206
SN - 1937-3341
VL - 25
SP - 1493
EP - 1503
JO - Tissue Engineering - Part A
JF - Tissue Engineering - Part A
IS - 21-22
ER -